Scalable Manufacturing With Perfusion-Adherent Bioreactors
Conveyxo’s proprietary bioreactor platform is designed to deliver high-yield, cost-effective, and clinically scalable exosome manufacturing.
By combining 3D scaffold architecture for optimal cell adherence, and automated closed-system operation, the platform supports consistent production of therapeutic-grade exosomes from discovery through cGMP scale.
High-Performance Bioreactor Design
Our platform uses advanced engineering to increase throughput, improve process control, and deliver consistent exosome yields at any production scale.
A structured 3D scaffold increases adherence surface area and optimizes flow across the reactor, improving yield over conventional fixed-bed or bead-based systems.
Driven by microfluidics, the platform offers precise control over media and oxygen flow for optimal product development.
Automation reduces manual intervention and minimizes batch variability, resulting in a more robust and reliable manufacturing process.
Our high-throughput mini-bioreactor tests up to 24 conditions in parallel using small volumes, reducing development time and enabling early cost modeling. While cell expansion at this scale is typically done in a 2D format, Exo-Harvest enables the use of the 3D scaffold during optimization, resulting in unique benefits.
Accelerated and Cost-Optimized Process Development
The performance of different geometries can be compared, in addition to traditional parameters like media composition, leading to higher yields. An AI tool selects the best geometry using the process data and microfluidic simulations.
For more information, access EXO-Harvest.
Transferring the optimal process conditions to larger reaction volumes becomes much more predictable, facilitating scale-up.It also allows the cost per dose of each condition to be extrapolated to a large-scaleGMP process.
A Platform Built for Every Stage of Manufacturing
From discovery to clinical supply, the platform automated workflows across small-scale optimization, mid-scale production, and large cGMP lots. This ensures consistent product quality and a scalable path from concept to clinic.